Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

Entero Healthcare Solutions / Equity Bottom-Up

<ul>
<li>Entero Healthcare differentiates itself through a dual-value model that combines large-scale demand fulfillment with integrated commercial solutions with a massive TAM of <strong>INR 3.3 Trillions.</strong>
</li>
<li>Management is aggressively targeting the high-margin MedTech segment, with revenue from this vertical expected to cross <strong>INR 1,000 crore</strong> on an annualized basis.</li>
<li>Entero is becoming positive operating cash flow in H2FY26 supported by reduction Net Operating Working Capital from 69 to 60 days. </li>
</ul>


Entero Healthcare differentiates itself through a dual-value model that combines large-scale demand fulfillment with integrated commercial solutions with a massive TAM of INR 3.3 Trillions.

Management is aggressively targeting the high-margin MedTech segment, with revenue from this vertical expected to cross INR 1,000 crore on an annualized basis.
Entero is becoming positive operating cash flow in H2FY26 supported by reduction Net Operating Working Capital from 69 to 60 days. 


Entero Healthcare: New Titan of Pharma Distribution

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

LG Energy Solution / Equity Capital Markets

<ul>
<li>We take a look at the Asia Pacific IPO pipeline for 2022. This list has been compiled on a best effort basis from tracking company filings and other sources.</li>
<li>For readers who aren't familiar with our coverage, we aim to cover all IPOs and placements with a minimum deal size of US$100m across Asia-Pacific (ex A-shares), including China ADRs. </li>
<li>The deals you see in this note are only a part of our full IPO pipeline tracker. Feel free to drop us a message for additional information on these IPOs.</li>
</ul>


We take a look at the Asia Pacific IPO pipeline for 2022. This list has been compiled on a best effort basis from tracking company filings and other sources.
For readers who aren't familiar with our coverage, we aim to cover all IPOs and placements with a minimum deal size of US$100m across Asia-Pacific (ex A-shares), including China ADRs. 
The deals you see in this note are only a part of our full IPO pipeline tracker. Feel free to drop us a message for additional information on these IPOs.


APAC IPOs & Placements, Aequitas Research

Clarence Chu

APAC IPOs & Placements

Sahajanand Medical Technologies / Equity Capital Markets

Sahajanand Medical Technologies (2585275D IN)

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sahajanand-medical-technologies-ltd" target="_blank" data-smartkarma-citation="entities:35324:1" rel="noopener">Sahajanand Medical Technologies Ltd (544309Z IN)</a> is looking to raise US$202m in its upcoming India IPO. The deal will be run by Axis Capital, Bank of America, Edelweiss and UBS.</li>
<li>Sahajanand Medical Technologies is a medical devices company that researches, designs, develops, manufactures and markets vascular devices.</li>
<li>The product portfolio is led by its flagship coronary stent, Supraflex Cruz, where the product had been implanted in over 400,000 patients globally as of Mar 2021.</li>
</ul>



Sahajanand Medical Technologies Ltd (544309Z IN) is looking to raise US$202m in its upcoming India IPO. The deal will be run by Axis Capital, Bank of America, Edelweiss and UBS.
Sahajanand Medical Technologies is a medical devices company that researches, designs, develops, manufactures and markets vascular devices.
The product portfolio is led by its flagship coronary stent, Supraflex Cruz, where the product had been implanted in over 400,000 patients globally as of Mar 2021.


Sahajanand Medical Technologies Pre-IPO Tearsheet

API Holdings Limited / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/api-holdings-limited" target="_blank" data-smartkarma-citation="entities:35071:1" rel="noopener">API Holdings Limited (1810068D IN)</a> is looking to raise US$843m in its India IPO. The deal will be run by Kotak, Morgan Stanley, Bank of America, Citigroup, and JM Financial.  </li>
<li>API Holdings, most known for its consumer healthcare super app, PharmEasy, is an amalgamation of a number of healthcare brands in India. </li>
<li>PharmEasy enables on-demand, home delivery of pharmaceutical products to consumers. As per RedSeer, it is India’s largest digital healthcare platform (based on GMV of products and services sold in FY21).</li>
</ul>



API Holdings Limited (1810068D IN) is looking to raise US$843m in its India IPO. The deal will be run by Kotak, Morgan Stanley, Bank of America, Citigroup, and JM Financial.  
API Holdings, most known for its consumer healthcare super app, PharmEasy, is an amalgamation of a number of healthcare brands in India. 
PharmEasy enables on-demand, home delivery of pharmaceutical products to consumers. As per RedSeer, it is India’s largest digital healthcare platform (based on GMV of products and services sold in FY21).


API Holdings (PharmEasy) Pre-IPO Tearsheet

India

API Holdings Limited distributes health care products to providers, retail outlets, and end consumers.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

API Holdings Limited (1810068D IN)

Entero Healthcare: New Titan of Pharma Distribution

Entero Healthcare's dual-value model targets high-margin MedTech segment, aiming for INR 1,000 crore revenue with positive cash flow expected in...

Nimish Maheshwari

Aequitas 2022 Asia IPO Pipeline

We take a look at the Asia Pacific IPO pipeline for 2022. This list has been compiled on a best effort basis from tracking company filings and...

Sumeet Singh

Sahajanand Medical Technologies Pre-IPO Tearsheet

Sahajanand Medical Technologies Ltd (544309Z IN) is looking to raise US$202m in its upcoming India IPO. The deal will be run by Axis Capital, Bank...

Clarence Chu

API Holdings (PharmEasy) Pre-IPO Tearsheet

API Holdings Limited (1810068D IN) is looking to raise US$843m in its India IPO. The deal will be run by Kotak, Morgan Stanley, Bank of America,...

Clarence Chu

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Entero Healthcare: New Titan of Pharma Distribution

​Entero Healthcare's dual-value model targets high-margin MedTech segment, aiming for INR 1,000 crore revenue with positive cash flow expected in...

Nimish Maheshwari

Aequitas 2022 Asia IPO Pipeline

We take a look at the Asia Pacific IPO pipeline for 2022. This list has been compiled on a best effort basis from tracking company filings and...

Sumeet Singh

Sahajanand Medical Technologies Pre-IPO Tearsheet

Sahajanand Medical Technologies Ltd (544309Z IN) is looking to raise US$202m in its upcoming India IPO. The deal will be run by Axis Capital, Bank...

Clarence Chu

API Holdings (PharmEasy) Pre-IPO Tearsheet

API Holdings Limited (1810068D IN) is looking to raise US$843m in its India IPO. The deal will be run by Kotak, Morgan Stanley, Bank of America,...

Clarence Chu

Entero Healthcare's dual-value model targets high-margin MedTech segment, aiming for INR 1,000 crore revenue with positive cash flow expected in...